Abstract
Background: Since late 2019, chronic renal disease, which complicates COVID-19 infection, has affected millions globally. Aim: To find key findings, prognosis, associated factors, outcomes, gaps, and recommendations related to COVID-19 in individuals with CKD. Methdology: A narrative review using keywords (COVID-19 OR SARS-CoV-2 OR 2019-nCoV Infections) AND (Chronic Kidney Disease OR CKD OR End-Stage Renal Disease OR Chronic Renal Failure OR Chronic Renal Insufficiency). Results: Analyzed systematic reviews, case-control studies, meta-analyses, observational, retrospective, randomised controlled trials, and case reports. The meta-analysis was conducted using a Random-Effects. The Q-statistic test for heterogeneity was conducted, with 11 degrees of freedom The pooled effect size estimate is 0.6663. The pooled estimate shows a statistically significant impact, with a 95% confidence interval ranging from 0.1834 to 1.1493. Age and comorbidities accelerate disease progression. Scientific Novelity: Briefly discusses how CKD affects COVID-19 patients. Conclusion: CKD greatly increases all-cause mortality and morbidity.
| Original language | English |
|---|---|
| Pages (from-to) | 3098-3108 |
| Number of pages | 11 |
| Journal | Research Journal of Pharmacy and Technology |
| Volume | 17 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2024 |
| Externally published | Yes |
Keywords
- Chronic kidney disease
- CKD
- Clinical predictors
- Corona virus
- COVID-19
- Management
- Prognosis
ASJC Scopus subject areas
- Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
- Pharmacology (medical)